Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation

Currently, there are no data on the secondary resistance of gastrointestinal stromal tumours to imatinib. Here, we report a case of metastatic gastrointestinal stromal tumour that relapsed during imatinib therapy. Mutation analysis showed that the imatinib-resistant liver tumour contained two c-kit...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakai, T, Kanda, T, Hirota, S, Ohashi, A, Shirai, Y, Hatakeyama, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409485/
https://www.ncbi.nlm.nih.gov/pubmed/15150562
http://dx.doi.org/10.1038/sj.bjc.6601819
_version_ 1782155776439091200
author Wakai, T
Kanda, T
Hirota, S
Ohashi, A
Shirai, Y
Hatakeyama, K
author_facet Wakai, T
Kanda, T
Hirota, S
Ohashi, A
Shirai, Y
Hatakeyama, K
author_sort Wakai, T
collection PubMed
description Currently, there are no data on the secondary resistance of gastrointestinal stromal tumours to imatinib. Here, we report a case of metastatic gastrointestinal stromal tumour that relapsed during imatinib therapy. Mutation analysis showed that the imatinib-resistant liver tumour contained two c-kit mutations.
format Text
id pubmed-2409485
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24094852009-09-10 Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation Wakai, T Kanda, T Hirota, S Ohashi, A Shirai, Y Hatakeyama, K Br J Cancer Clinical Currently, there are no data on the secondary resistance of gastrointestinal stromal tumours to imatinib. Here, we report a case of metastatic gastrointestinal stromal tumour that relapsed during imatinib therapy. Mutation analysis showed that the imatinib-resistant liver tumour contained two c-kit mutations. Nature Publishing Group 2004-06-01 2004-04-20 /pmc/articles/PMC2409485/ /pubmed/15150562 http://dx.doi.org/10.1038/sj.bjc.6601819 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Wakai, T
Kanda, T
Hirota, S
Ohashi, A
Shirai, Y
Hatakeyama, K
Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation
title Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation
title_full Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation
title_fullStr Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation
title_full_unstemmed Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation
title_short Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation
title_sort late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second kit mutation
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409485/
https://www.ncbi.nlm.nih.gov/pubmed/15150562
http://dx.doi.org/10.1038/sj.bjc.6601819
work_keys_str_mv AT wakait lateresistancetoimatinibtherapyinametastaticgastrointestinalstromaltumourisassociatedwithasecondkitmutation
AT kandat lateresistancetoimatinibtherapyinametastaticgastrointestinalstromaltumourisassociatedwithasecondkitmutation
AT hirotas lateresistancetoimatinibtherapyinametastaticgastrointestinalstromaltumourisassociatedwithasecondkitmutation
AT ohashia lateresistancetoimatinibtherapyinametastaticgastrointestinalstromaltumourisassociatedwithasecondkitmutation
AT shiraiy lateresistancetoimatinibtherapyinametastaticgastrointestinalstromaltumourisassociatedwithasecondkitmutation
AT hatakeyamak lateresistancetoimatinibtherapyinametastaticgastrointestinalstromaltumourisassociatedwithasecondkitmutation

Ejemplares similares